Bounce-back with black urine: A case report
A 33-year-old Congolese woman presented to our emergency department with a 2-month history of fatigue. Past medical history was significant for possible sickle cell trait, 2 uncomplicated pregnancies, total thyroidectomy for papillary thyroid cancer, bariatric surgery and previous transfusions due to micronutrient deficiencies. On investigation, she had microcytic anemia with a hemoglobin of 55 g/L, ascribed to iron and vitamin B12 deficiencies. She was administered intravenous iron, subcutaneous vitamin B12, transfused 4 units of red blood cells and discharged home with Hematology follow-up.
Thousands of men across the world have participated in randomized clinical trials testing the role of hormone therapy in the curative treatment of localized, high-risk prostate cancer. Over several decades, we have established that long-term hormone therapy improves survival, even in the setting of dose-escalated external beam radiation therapy (EBRT).1 Recently reported clinical trials suggest that for some men 18 months of hormone therapy may be a suitable duration that balances treatment efficacy with quality-of-life preservation.
We welcome 3 new associate editors: Drs Christopher Anker (University of Vermont Larner College of Medicine), Michael Buckstein (Icahn School of Medicine at Mount Sinai), and Jordan Kharofa (University of Cincinnati College of Medicine), whom were selected for their timely and thoughtful critiques as Red Journal reviewers. Although all 3 reviewers are experts in gastrointestinal (GI) radiation oncology, Dr Anker provides expertise in esophageal and rectal cancers, Dr Buckstein in liver cancers and translational science, and Dr Kharofa in pancreatic and anal cancers.
To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer.
We thank the authors1 for their letter highlighting the critical issues facing the feasibility and efficacy of stereotactic ablative radiation (SAbR) as a boost for patients with cervical cancer unable to receive standard brachytherapy.
We applaud the University of Texas Southwestern Department of Radiation Oncology for conducting “A phase II trial of stereotactic ablative radiotherapy as a boost for locally advanced cervical cancer,” a necessary prospective study on definitive dose delivery for patients unable to undergo brachytherapy.1 The involved trialists were undoubtedly deliberate and meticulous in its design and e xecution, akin to their groundbreaking work with lung stereotactic body radiation therapy (SBRT). Although these results unfortunately showed high rates of rectal toxicity, the data does not indicate a failure of SBRT, but ra...
A 58-year-old female presents with a 1-year history of hematochezia, 20-pound weight loss, and increased straining with bowel movements. She denies increased bowel frequency or change in stool caliber. Her medical history is notable for irritable bowel syndrome, but otherwise unremarkable. She has no family history of malignancy and does not take any prescribed medications or supplements. She denies abdominal pain, bone pain, or any symptoms concerning for metastatic disease. Her initial physical examination was notable for an Eastern Cooperative Oncology Group performance status of 0, and presence on digital rectal examin...
In Africa, there were over 846,000 new cancer cases and 591,000 deaths in 2012. These figures are projected to rise to 1.27 million cases and 0.97 million deaths annually by 20301 as a result of population growth and aging alone.
Introduction: Bioelectrical impedance vector analysis (BIVA) is a non-invasive method for measuring body composition. The “InForma” trial has been designed to measure improvement of adherence to a healthy diet and/or to increase physical activity in order to promote weight loss in overweight or obese breast cancer survivors. Breast cancer survivors frequently face progressive weight gain and diminution of physical activity.
Introduction: Breast cancer (BC) is the most common cancer in women and the 5-year survival rate is 82% in Europe. Obesity, metabolic syndrome and diabetes are associated with an increased risk of BC and BC recurrence. Physical activity (PA), Mediterranean diet (MeD) and low glycemic index (GI) or high fiber diets, however, are protective.
Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a chronic and progressive respiratory disease, commonly associated with alterations of nutritional status. Among these, low Vitamin D levels are frequent and related to disease severity, risk of exacerbations and annual hospitalizations and general health status of individual patients.